These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 29674332

  • 1. Potent Sodium/Glucose Cotransporter SGLT1/2 Dual Inhibition Improves Glycemic Control Without Marked Gastrointestinal Adaptation or Colonic Microbiota Changes in Rodents.
    Du F, Hinke SA, Cavanaugh C, Polidori D, Wallace N, Kirchner T, Jennis M, Lang W, Kuo GH, Gaul MD, Lenhard J, Demarest K, Ajami NJ, Liang Y, Hornby PJ.
    J Pharmacol Exp Ther; 2018 Jun; 365(3):676-687. PubMed ID: 29674332
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents.
    Oguma T, Nakayama K, Kuriyama C, Matsushita Y, Yoshida K, Hikida K, Obokata N, Tsuda-Tsukimoto M, Saito A, Arakawa K, Ueta K, Shiotani M.
    J Pharmacol Exp Ther; 2015 Sep; 354(3):279-89. PubMed ID: 26105952
    [Abstract] [Full Text] [Related]

  • 4. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
    Nagata T, Fukazawa M, Honda K, Yata T, Kawai M, Yamane M, Murao N, Yamaguchi K, Kato M, Mitsui T, Suzuki Y, Ikeda S, Kawabe Y.
    Am J Physiol Endocrinol Metab; 2013 Feb 15; 304(4):E414-23. PubMed ID: 23249697
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery.
    Martinussen C, Veedfald S, Dirksen C, Bojsen-Møller KN, Svane MS, Wewer Albrechtsen NJ, van Hall G, Kristiansen VB, Fenger M, Holst JJ, Madsbad S.
    Am J Physiol Endocrinol Metab; 2020 Jun 01; 318(6):E956-E964. PubMed ID: 32182123
    [Abstract] [Full Text] [Related]

  • 7. Improved glycemic control in mice lacking Sglt1 and Sglt2.
    Powell DR, DaCosta CM, Gay J, Ding ZM, Smith M, Greer J, Doree D, Jeter-Jones S, Mseeh F, Rodriguez LA, Harris A, Buhring L, Platt KA, Vogel P, Brommage R, Shadoan MK, Sands AT, Zambrowicz B.
    Am J Physiol Endocrinol Metab; 2013 Jan 15; 304(2):E117-30. PubMed ID: 23149623
    [Abstract] [Full Text] [Related]

  • 8. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.
    Zambrowicz B, Ogbaa I, Frazier K, Banks P, Turnage A, Freiman J, Boehm KA, Ruff D, Powell D, Sands A.
    Clin Ther; 2013 Aug 15; 35(8):1162-1173.e8. PubMed ID: 23911260
    [Abstract] [Full Text] [Related]

  • 9. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
    Yoshii A, Nagoshi T, Kashiwagi Y, Kimura H, Tanaka Y, Oi Y, Ito K, Yoshino T, Tanaka TD, Yoshimura M.
    Cardiovasc Diabetol; 2019 Jul 01; 18(1):85. PubMed ID: 31262297
    [Abstract] [Full Text] [Related]

  • 10. What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.
    Dominguez Rieg JA, Rieg T.
    Diabetes Obes Metab; 2019 Apr 01; 21 Suppl 2(Suppl 2):43-52. PubMed ID: 31081587
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The Na+-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer.
    Koepsell H.
    Pharmacol Ther; 2017 Feb 01; 170():148-165. PubMed ID: 27773781
    [Abstract] [Full Text] [Related]

  • 14. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity.
    Yamamoto K, Uchida S, Kitano K, Fukuhara N, Okumura-Kitajima L, Gunji E, Kozakai A, Tomoike H, Kojima N, Asami J, Toyoda H, Arai M, Takahashi T, Takahashi K.
    Br J Pharmacol; 2011 Sep 01; 164(1):181-91. PubMed ID: 21410690
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction.
    Connelly KA, Zhang Y, Desjardins JF, Thai K, Gilbert RE.
    Cardiovasc Diabetol; 2018 Jul 07; 17(1):99. PubMed ID: 29981571
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.
    Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, Thomson SC, Koepsell H, Vallon V.
    Am J Physiol Renal Physiol; 2014 Jan 07; 306(2):F188-93. PubMed ID: 24226519
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.